Table 2 Treatment-related adverse events reported with infusion of NK cells (n = 24a)

From: Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b/2 trial

Preferred termb, n (%)

Cohort 1

Cohort 2

Cohort 3

Cohort 4

All cohort

(1 × 109, n = 4)

(2 × 109, n = 6)

(4 × 109, n = 7)

(8 × 109, n = 7)

(n = 24)

Grade1–2

Grade3-4

Grade1–2

Grade3-4

Grade1–2

Grade3-4

Grade1–2

Grade3-4

Grade1–2

Grade3-4

Fever

2 (50.0)

0

0

0

0

0

2 (28.6)

0

4 (16.7)

0

Fatigue

0

0

1 (16.7)

0

0

0

2 (28.6)

0

3 (12.5)

0

Chill

0

0

0

0

0

0

2 (28.6)

0

2 (8.3)

0

Rash

0

0

0

0

0

0

1 (14.3)

0

1 (4.2)

0

GVHDc

0

0

0

0

0

0

0

0

0

0

  1. aP25 withdrew from the clinical trial without receipting NK cells treatment due to the chemotherapy toxicity
  2. bMedical Dictionary for Regulatory Activities version 23.1, graded according to CTCAE version 5.0
  3. cGVHD, Graft-versus-host disease
Back to article page